Recent Updates
Recently added Catalysts

JZP898

Phase 1

Advanced Solid Tumor | Small molecule | Oncology |Jazz Pharmaceuticals plc|Last Updated: Dec 16, 2025

Target and mechanism

Molecular targetIFN ⍺2b
Target classCytokine
ModalitySmall molecule

Success Probability

Subscribe to view

Market & Valuation

Subscribe to view

Trial Design

CONTROLLED
Total Trials1
Total Enrollment177

FDA Designations

No designations recorded

Clinical trial landscape

JZP898 · 1 trial · 2 indications

Phase 1 1
NCT06108050JZP898 Intravenous Infusion as Monotherapy and Combination With Pembrolizumab in Adults With Advanced/Metastatic Solid TumorsAdvanced Solid Tumor
RECRUITING177 Analytics
PHASE1RECRUITING
JZP898 Intravenous Infusion as Monotherapy and Combination With Pembrolizumab in Adults With Advanced/Metastatic Solid Tumors
Advanced Solid Tumor
NCT06108050177
Unlock trial analytics

Study Endpoints

Primary Endpoints

Number of Participants with Dose Limiting Toxicities in Monotherapy and Combination Therapy
Up to 36 months
Incidence of TEAEs and SAEs in Monotherapy and Combination Therapy
Up to 36 months
Incidence of dose interruptions, discontinuation, and reductions due to TEAEs in Monotherapy and Combination Therapy
Up to 36 months
Objective Response Rate (ORR) As Assessed by the Investigator In Combination Therapy
Up to 36 months

Secondary Endpoints

Pharmacokinetic Parameter: Maximum Concentration (Cmax) of JZP898 in Monotherapy and Combination Therapy
Up to 36 months
Pharmacokinetic Parameter: Time to Maximum Concentration (Tmax) of JZP898 in Monotherapy and Combination Therapy
Up to 36 months
Pharmacokinetic Parameter: Terminal Elimination Half-life (t½) of JZP898 in Monotherapy and Combination Therapy
Up to 36 months
Unlock Study Endpoints

Study Design & Arms

AllocationNON_RANDOMIZED
MaskingNONE
ModelSEQUENTIAL
PurposeTREATMENT

Treatment Arms

ArmTypeDescription
Part A1 Dose Exploration: JZP898 monotherapyEXPERIMENTAL -
Part A2 Dose Exploration: JZP898 in combination with pembrolizumabEXPERIMENTAL -
Part B Combination Expansion: JZP898 in combination with pembrolizumabEXPERIMENTAL -

Interventions

NameTypeDescription
JZP898DRUGInvestigational drug monotherapy
PembrolizumabDRUGAnti-PD1 antibody
Unlock Study Design Details

Eligibility Criteria

Age Range18 Years to N/A
SexALL
Healthy VolunteersNo
Study Sites10

Inclusion Criteria * Adult ≥ 18 years of age * Histological or cytological diagnosis of advanced or metastatic solid tumor. 1. Previously treated participants with solid tumors that are amenable to CPI therapy (eg. NSCLC, melanoma, HNSCC, RCC, HCC, gastroesophageal carcinomas, UC, or CRC \[MSI-H...

Countries:United States
Unlock Eligibility Criteria

Competitive Landscape -Other Solid Tumors 9 trials (matched to "Advanced Solid Tumor")

CompanyTickerTrialsLead PhaseDrugs
Merck & Co., Inc.MRK2PHASE2pembrolizumab
Incyte CorporationINCY1PHASE2Chemotherapy, Retifanlimab
Iovance Biotherapeutics IncIOVA2PHASE2E7 TCR-T cells, Aldesleukin
Novartis AG Sponsored ADRNVS1PHASE1KFA115, pembrolizumab
AstraZeneca PLCAZN1 - Trastuzumab deruxtecan
Unlock Competitive Intelligence

Frequently asked questions about JZP898

What is JZP898 used for in advanced solid tumors?

JZP898 is an investigational small molecule being developed for the treatment of advanced solid tumors. It is currently in Phase 1 clinical trials as a monotherapy and in combination with pembrolizumab for adults with advanced or metastatic solid tumors. The drug is administered via intravenous infusion.

What does JZP898 target?

JZP898 targets IFN alpha 2b, a cytokine involved in immune signaling. By targeting this molecule, the drug aims to modulate the immune response against tumor cells. This mechanism is being studied in the context of advanced solid tumors, where immune modulation can potentially enhance anti-tumor activity.

Who makes JZP898?

JZP898 is being developed by Jazz Pharmaceuticals plc, a biopharmaceutical company listed on the NASDAQ under the ticker symbol JAZZ. The company is conducting clinical trials to evaluate the safety and efficacy of JZP898 in patients with advanced solid tumors.

What phase is JZP898 in?

JZP898 is currently in Phase 1 clinical development. It is an investigational drug, meaning it has not yet been approved by regulatory authorities. The ongoing Phase 1 trial is recruiting participants to assess the drug's safety, tolerability, and preliminary efficacy in advanced solid tumors.

What clinical trials is JZP898 in?

JZP898 is being studied in a Phase 1 clinical trial with the identifier NCT06108050. This trial evaluates JZP898 as a monotherapy and in combination with pembrolizumab in adults with advanced or metastatic solid tumors. The study is recruiting participants in the United States and has a target enrollment of 177 patients.

Is JZP898 the same as IFN alpha 2b?

JZP898 is not the same as IFN alpha 2b; rather, it targets IFN alpha 2b. JZP898 is a small molecule designed to interact with this cytokine, which is part of the immune system's signaling pathways. The drug is being investigated for its potential role in treating advanced solid tumors.